April 26, 2019
Takeda Pharmaceutical said on April 25 that it has filed a new drug application in Japan for cabozantinib, a cancer drug licensed from US partner Exelixis, for the treatment of unresectable/metastatic renal cell carcinoma (RCC). Takeda grabbed Japan rights to...read more